Skip to main content
Clinical Trials/CTRI/2021/10/037187
CTRI/2021/10/037187
Recruiting
未知

A prospective, interventional, randomized, double-blind, parallel, placebo-controlled study to assess the efficacy of two doses of Curcuwin Ultra plus on joint health and muscle strength in subjects with mild knee osteoarthritis.

OmniActive Health Technologies0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: M179- Osteoarthritis of knee, unspecified
Sponsor
OmniActive Health Technologies
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Male and/or female subject aged between 35 and 75 years (both limits inclusive).
  • 2\.Subject with clinical diagnosis of unilateral or bilateral knee osteoarthritis for at least greater than 3 months, as presented by pain in the knee at least for last 3 months.
  • 3\.Subject with index knee joint pain rated ââ?°Â¤ 44 on a 100\-point Pain\-VAS scale.
  • 4\.Subject with knee osteoarthritis grade II (Kellgren\- Lawrence classification).
  • 5\.Subject willing to be involved in regular physical activity such as walking, climbing stairs, recording forms, eating, exercise behaviors, etc.
  • 6\.Subject who is able to walk for at least 6 minutes at a moderate\-to\-brisk pace on the treadmill.
  • 7\.Subject willing to avoid NSAIDs and other anti\-inflammatory medications during the study period.
  • 8\.Subject who agrees to stay weight stable during the study period.
  • 9\.Subject who is able to follow the instruction for investigational product administration and is 100% compliant with an investigational product during the Run\-In Period.
  • 10\.Female subject of child bearing potential practicing an acceptable method of birth control such as Intrauterine Device in place for at least 3 months prior to the start of the study and remaining in place during the study period, contraceptive transdermal, injection or implants, non\-hormonal or hormonal, abstinence: Subjects planning abstinence shall agree to have a documented second acceptable method of birth control should the subject become sexually active during the course of her study participation as judged by the investigator(s)/study physician and agree to follow the same during treatment.

Exclusion Criteria

  • 1\.Subject who is pregnant, nursing, or planning a pregnancy within the study participation period.
  • 2\.Subject with positive Urine Pregnancy Test at Screening Visit.
  • 3\.Subject with a previous history of knee osteoarthritis for more than 3 years.
  • 4\.Subject with a previous history of any knee joint replacement surgery.
  • 5\.Subject with moderate to severe knee osteoarthritis in Grade III or IV as per Kellgren and Lawrence Scale.
  • 6\.Subject unwilling to refrain from the use of NSAIDs (including low dose aspirin 50 mg/day for cardiovascular health) or herbal/ nutraceutical supplements for joint health or local analgesics during the study duration.
  • 7\.Subject with history of hypothyroidism and have thyroid deficiency except euthyroid.
  • 8\.History of allergy or sensitivity to Curcumin, and related compounds or any component of the formulation.
  • 9\.Subject with use of any immunosuppressive drugs in the last 3 months (including steroids).
  • 10\.Subject with poorly controlled hypertension (Systolic Blood Pressure ââ?°Â¥140 mm Hg and Diastolic Blood Pressure ââ?°Â¥ 90 mm Hg).

Outcomes

Primary Outcomes

Not specified

Similar Trials